InfuSystem HoldingsINFU
Recorded

InfuSystem Holdings 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration23 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and welcome to the InfuSystem Holdings Third Quarter 2026 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touchtone phone. To withdraw your question, please press star then two. Please note, this event is being recorded. I would like to turn the conference over to Mr. Stefan Eftychiou with Bristol Investor Relations.

Stefan EftychiouVP of Investor Relations

Please go ahead. Good morning, and thank you for joining us today to review InfuSystem's financial results for the third quarter ended September 30, 2026.

Stefan EftychiouVP of Investor Relations

With us today on the call are Carrie Lachance, Chief Executive Officer, and Barry Steele, Chief Financial Officer. After the conclusion of today's prepared remarks, we will open the call for questions. Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of InfuSystem during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under risk factors and documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2025.

Stefan EftychiouVP of Investor Relations

Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. InfuSystem does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law. Additionally, management may discuss certain non-GAAP financial measures during today's call. Reconciliations of those measures to the most directly comparable GAAP measures are contained in today's earnings release. Now, I'd like to turn the call over to Carrie Lachance, Chief Executive Officer of InfuSystem.

Carrie LachanceCEO

Carrie? Thank you, Stephane, and good morning, everyone.

Carrie LachanceCEO

Welcome to InfuSystem's third quarter fiscal year 2026 earnings call. Thank you for joining us today. I will provide a third quarter overview highlighting our progress in the quarter, then Barry will provide additional detail regarding our financial results and the primary drivers of the quarter. I will then come back with some closing comments before opening the line to questions. We are pleased with the third quarter results and believe they demonstrate continued execution of our profitable growth strategy. During the quarter, we achieved record revenue of $37.6 million, and after adjusting for the previously announced GE Healthcare contract restructuring, generated pro forma revenue growth of 10.2%. Pro forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter.

Carrie LachanceCEO

We also expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior year period. These results reflect the continued strength of our diversified operating platform and the progress we have made executing our strategic initiatives. The most encouraging aspect of the quarter was the continued growth we are seeing from investments made over the last several years. Our Oncology business remains strong, while our Wound Care business continued to scale rapidly. In particular, our compression therapy product lines focused on lymphedema treatments are becoming an increasingly meaningful contributor to our growth and further validate our strategy of leveraging our existing Patient Services infrastructure, clinical capabilities, and payer relationships to support complementary therapy categories. Wound Care revenue increased 112% during the quarter, including approximately $1.6 million of growth from compression therapy products. Lymphedema remains a chronically underserved market, and we believe there is still a lot of runway ahead.

Carrie LachanceCEO

We also continue to benefit from actions taken to improve the profitability of Device Solutions. The restructuring of our GE Healthcare contract and ongoing operational improvement initiatives contributed to higher profitability while helping us improve operating cash flow and further strengthening our balance sheet. At the same time, ERP-related expenses continued to decline as implementation activities gave way to stabilization and optimization efforts. As we look ahead, we continue to see opportunities to improve the economics of our Patient Services platform through additional workflow automation and software-enabled process improvements. We believe reducing the cost of processing third-party payer claims can further enhance operating efficiency while supporting growth opportunities in Wound Care and other therapy categories. We expect to begin making modest additional investments in these initiatives during the fourth quarter.

Carrie LachanceCEO

These investments are intended to build upon the technology foundation we have already established and further strengthening our ability to scale efficiently over time. Based on the performance through the first nine months of the year, we are reaffirming our full-year guidance. We continue to expect pro forma revenue growth of 6%-8% for 2026 after adjusting for the impact of the GE Healthcare contract restructuring and continue to expect Adjusted EBITDA margins to remain in the low to mid-20% range. We remain focused on disciplined execution, profitable growth, and creating long-term value for our shareholders. With that, I will turn the call over to Barry.

Barry SteeleCFO

Thank you, Carrie, and good morning, everyone. I will provide some additional detail regarding the financial results and the primary drivers for the quarter. Third quarter revenue increased 3% to $37.6 million. After adjusting for the impact of the GE Healthcare contract restructuring, revenue grew 10.2% on a pro forma basis. The quarter benefited from strong performance in Oncology and Wound Care, partially offset by lower Device Solutions revenue associated with the contract restructuring and lower equipment sales activity. Within Patient Services, Oncology grew 7.2% and continued to perform well, driven by additional treatment volume, improved reimbursement hit rates, and collections. Wound Care again delivered exceptional growth, led by compression therapy products and negative pressure wound therapy. While we recorded certain reserves associated with Adjustable Compression Wraps during the quarter, underlying demand for the category remained strong, and Wound Care exceeded our prior forecast. Within Device Solutions, results were mixed.

Barry SteeleCFO

Equipment rentals, depot services, and non-GE field services performed well. Adjusting for the GE Healthcare restructuring, biomedical services revenue grew 19.8% on a pro forma basis. Biomedical services, in particular, benefited from both strong device repair volume at our repair depots and increased field-based projects outside of the GE Healthcare contract. These positives were partially offset by lower equipment sales and softer disposable product revenue than anticipated during the quarter. Gross profit increased 4.4% year-over-year, and gross margin expanded to 57.8% from 57.1% in the prior year period. The largest positive contributors to profitability continue to be the improved economics associated with the GE Healthcare contract restructuring, ongoing procurement initiatives, productivity improvements, and the favorable impact of higher revenue. These factors more than offset pressure from product mix changes within Patient Services, reserve activity, and inflationary cost increases.

Barry SteeleCFO

Net income was $3.2 million, or $0.15 per diluted share, compared to $2.3 million, or $0.11 per diluted share in the prior year period. Adjusted EBITDA increased 12.5% to $9.4 million, and Adjusted EBITDA margin expanded to 24.9% compared to 22.8% in the prior year period. The improvement reflects the benefits of revenue growth, the previously announced GE Healthcare contract restructuring, operational improvement initiatives, and lower ERP-related implementation expenses, partially offset by changes in revenue mix and other normal cost pressures. Turning briefly to cash flow and the balance sheet. Operating cash flow for the first nine months of 2026 increased 5% to $18.1 million, including $10.4 million in the third quarter. During the same period, the company invested $8.7 million in medical equipment and repurchased approximately $5 million of common stock.

Barry SteeleCFO

We ended the quarter with $64.1 million of liquidity and reduced net debt by $8.9 million during the quarter to approximately $10.6 million, or 0.32 times trailing Adjusted EBITDA, down from 0.61 times at the end of June. These metrics were achieved despite experiencing approximately $5 million of temporary working capital pressure during the quarter related to billing and invoicing issues following our ERP implementation. Importantly, this was not driven by customer demand, reimbursement changes, or credit deterioration. The majority of the increase relates to invoices that were either delayed or required customer-specific revisions before payment could be processed. These revisions were primarily related to customer-required invoice formatting associated with the new invoice format, rather than errors in the underlying data. We identified the issue during the third quarter, implemented corrective actions, and collection trends improved steadily through September and into October.

Barry SteeleCFO

Based on October collection activity, we estimate roughly $1.3 million of the excess receivable balance has already converted to cash. We expect further normalization of collections over the coming months. Overall, we remain very pleased with the continued improvement in cash generation and balance sheet flexibility. Regarding guidance, our updated forecast remained consistent with the outlook communicated earlier this year. Based on our current expectations, we continue to expect full-year pro forma revenue growth within our previously communicated range of 6%-8%, and Adjusted EBITDA margins in the low to mid-20% range, including the modest additional investments Carrie mentioned that we expect to begin in the fourth quarter. Our most recent forecast remains supportive of these objectives. I will now turn the call back over to Carrie.

Carrie LachanceCEO

Thanks, Barry. Our third-quarter progress reinforces the focus for the balance of the year: advancing our growth priorities, executing with discipline, and strengthening our platform to support greater scale and long-term value creation. Operator, we are ready for the Q&A portion of the call.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day